Press Releases May 6, 2026 09:00 AM

Prospect Capital Schedules Third Fiscal Quarter Earnings Release and Conference Call

Prospect Capital Corporation announces Q3 2026 earnings release and conference call schedule

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
PSEC

Prospect Capital Corporation announced it will release its fiscal third quarter earnings results for the period ending March 31, 2026, after market close on May 7, 2026, followed by a conference call on May 8, 2026. The company provides investment focused on middle market private companies, aiming for income and capital appreciation.

Prospect Capital Schedules Third Fiscal Quarter Earnings Release and Conference Call
PSEC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Prospect Capital Corporation will file its Q3 2026 Form 10-Q and release earnings on May 7, 2026.
  • The company specializes in lending to and investing in middle market privately-held companies.
  • A conference call will be held on May 8, 2026 to discuss the results and business outlook.

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended March 31, 2026 and to issue its earnings press release on Thursday, May 7, 2026, after the close of the markets.

The Company will host a conference call on Friday, May 8, 2026 at 9:00 a.m. Eastern Time. The conference call dial-in number will be 888-338-7333. A recording of the conference call will be available for approximately 30 days. To hear a replay, call 855-669-9658 and use passcode 1182378.

The conference call will also be available via a live listen-only webcast on the Company’s website, www.prospectstreet.com. Please allow extra time prior to the call to visit the site and download any necessary software that may be needed to listen to the Internet broadcast.

About Prospect Capital Corporation

Prospect is a business development company that primarily lends to and invests in middle market privately-held companies. Prospect’s investment objective is to generate both current income and long-term capital appreciation.

Prospect has elected to be treated as a business development company under the Investment Company Act of 1940. Prospect has elected to be treated as a regulated investment company under the Internal Revenue Code of 1986.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, whose safe harbor for forward-looking statements does not apply to business development companies. Any such statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that we may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements. Such statements speak only as of the time when made, and we undertake no obligation to update any such statement now or in the future.

For additional information, contact:

Grier Eliasek, President and Chief Operating Officer
grier@prospectcap.com
Telephone (212) 448-0702


Risks

  • Forward-looking statements included may not materialize due to various uncontrollable future events.
  • As a business development company, performance is subject to market and credit risks related to lending to middle market firms.
  • Uncertainties inherent in economic and regulatory conditions could affect future results.

More from Press Releases

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc. Jun 15, 2026 Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform Jun 15, 2026 QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers Jun 15, 2026 Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 Jun 15, 2026 Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing Jun 15, 2026